Although LDL-C lowering is the cornerstone of atherosclerotic risk reduction, other lipids are important to cardiovascular (CV) disease. Indeed, triglycerides have received increased attention as a major atherogenic lipid. In a stimulating poster session at AHA, the association of triglycerides with CV disease was explored.
Among close to 200,000 residents in Ontario with ASCVD, increased triglycerides were associated with recurrent adverse clinical outcomes. 20% of those with ASCVD had elevated TG levels despite controlled LDL-C, meeting criteria for the REDUCE-IT trial, which showed that icosapent ethyl 4 g/day reduced CV events in those with ASCVD or DM with TG >135mg/dL. In another analysis from the Rochester Epidemiology Project, severe isolated hypertriglyceridemia (TG >500 mg/dL) was identified in 3,800 patients, of whom 542 had primary hypertriglyceridemia, yielding an overall prevalence of 2%. This population is at increased risk of pancreatitis as well as ASCVD. A rarer condition called familial chylomicronemia syndrome (FCS) is when a patient has TG >750 and recurrent pancreatitis. Prior estimates were 1:1 million, but a study from Johns Hopkins presented at the AHA suggested it is much higher at 13:1 million. Further, these investigators demonstrated that patients with FCS, while having high risk of pancreatitis, actually had a lower risk of ASCVD than those with secondary hypertriglyceridemia.